clinical trial · NCT06806657
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
CSL Behring·phase4·active not recruiting·n = 18
Hereditary AngioedemaGaradacimab
brief summary
This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 months in participants aged greater than or equal to (\>=) 12 years with HAE.
started
Apr 28, 2025
primary completion
Jun 23, 2026
completion
Jun 23, 2026
last updated
May 14, 2026
official title
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE ≥ 12 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol